Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Opthea Limited OPT
$3.74
На 18:03, 12 мая 2023
+274.33%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
222953536.00000000
-
week52high
8.50
-
week52low
3.25
-
Revenue
90683
-
P/E TTM
-2
-
Beta
0.28740400
-
EPS
-2.46000000
-
Last Dividend
0.00000000
-
Next Earnings Date
29 авг 2022 г. в 04:00
Описание компании
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | 26 апр 2022 г. | |
| Citigroup | Buy | 17 ноя 2020 г. | |
| Truist Securities | Buy | 11 ноя 2020 г. | |
| SVB Leerink | Outperform | 11 ноя 2020 г. | |
| Oppenheimer | Outperform | 11 ноя 2020 г. | |
| Citigroup | Buy | Buy | 16 сент 2022 г. |
| HC Wainwright & Co. | Buy | 08 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Opthea To Present at SVB Leerink Global Biopharma Conference
GlobeNewsWire
06 февр 2023 г. в 06:00
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at SVB Leerink's Global Biopharma Conference being held virtually on February 14-16, 2023.
Opthea To Present at Sequire Biotechnology Conference
GlobeNewsWire
30 янв 2023 г. в 06:00
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023.
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
GlobeNewsWire
12 дек 2022 г. в 10:08
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT).
Opthea to Present at the FLORetina 2022 Congress
GlobeNewsWire
06 дек 2022 г. в 06:00
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022.
Optiva Inc. (RKNEF) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 12:13
Optiva Inc. (OTCPK:RKNEF) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Ali Mahdavi - Investor Relations John Giere - President and CEO Dinesh Sharma - VP of Finance Conference Call Participants Todd Coupland - CIBC Jason Senensky - Chapter Twelve Capital Operator Good day, everyone and welcome to the Optiva Inc. Third Quarter 2022 Financial Results Conference Call. I would like to remind everyone that today's conference is being recorded.